骨化三醇升高与实体瘤患者难治性恶性肿瘤高钙血症风险较高相关
该回顾性病历回顾纳入101例实体瘤合并恶性肿瘤高钙血症患者,45%存在骨化三醇升高。骨化三醇升高组对抗骨吸收治疗不完全反应率为80%,无升高组反应率为78%(P < .001)。两组死亡率无差异(P = .14)。
要点
- 实体瘤合并恶性肿瘤高钙血症患者中骨化三醇升高者占45%。
- 骨化三醇升高组抗骨吸收治疗不完全反应率80%,无升高组反应率78%(P < .001)。
- 两组转移性骨病比例(49% vs. 55%)及死亡率(P = .14)无显著差异。
核心结论
- 在恶性肿瘤高钙血症背景下,骨化三醇升高的患者对抗骨吸收治疗的反应明显低于无骨化三醇升高的患者。
- 骨化三醇升高似乎与低磷血症或PTHrP升高不相关,提示该条件下骨化三醇产生是自主性的,不受正常生理调控。
- 这些观察表明恶性肿瘤高钙血症患者的骨化三醇升高具有临床意义。
研究设计与样本
- 回顾性病历回顾,2008年至2017年,纳入本机构实体瘤合并恶性肿瘤高钙血症且伴骨化三醇升高的患者。
- 排除PTH依赖性高钙血症、肉芽肿性疾病及血液系统恶性肿瘤患者。
- 共101例符合条件患者纳入分析。
主要发现
- 101例 eligible 患者中,45例(45%)骨化三醇升高。
- 骨化三醇升高组中PTHrP升高者占76%,无骨化三醇升高组占52%。
- 骨化三醇升高组平均PTHrP值为36.3 ± 22 pg/mL,无骨化三醇升高组为37.4 ± 19 pg/mL,两组间无差异。
- 骨化三醇升高组对抗骨吸收治疗不完全反应率为80%,无骨化三醇升高组反应率为78%(P < .001)。
- 两组转移性骨病比例分别为49%与55%,无显著差异;两组死亡率无差异(P = .14)。
关键数值与推荐
- 骨化三醇升高组不完全反应率80%,无骨化三醇升高组反应率78%(P < .001)。
- 两组死亡率比较P = .14。
- 磷与骨化三醇相关性:总体Pearson r = -0.261(P = .016);无骨化三醇升高组Pearson r = -0.4(P = .0082)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypercalcemia of malignancy (HCM) is a common complication of advanced cancer. PTH-independent HCM may be mediated through different mechanisms: (1) humoral HCM, caused by the secretion of PTH-related peptide (PTHrP), (2) local osteolysis resulting from metastatic lesions, and (3) calcitriol-mediated hypercalcemia. Calcitriol-mediated HCM in patients with nonlymphomatous solid tumors is thought to be rare. METHODS: We performed a retrospective chart review from 2008 to 2017 to characterize further patients at our institution with solid tumors who had HCM with concomitant elevations in calcitriol. Patients with PTH-dependent hypercalcemia and patients with evidence of granulomatous disease were excluded, as were patients with hematologic malignancies. We hypothesized that patients with HCM and elevated calcitriol levels would respond less favorably to treatment with antiresorptive therapy compared with patients with HCM but without calcitriol elevation. We also aimed to assess mortality and determine if PTHrP and phosphorus levels correlate with calcitriol because both factors may alter calcitriol levels. RESULTS: Of 101 eligible patients, calcitriol was elevated in 45 (45%). PTHrP was elevated in 76% of patients with elevated calcitriol compared with 52% of patients without calcitriol elevation. The mean PTHrP value did not differ between patients with HCM and elevated calcitriol (36.3 ± 22 pg/mL) and those without calcitriol elevation (37.4 ± 19 pg/mL). Those with elevated calcitriol levels generally did not respond completely to antiresorptive treatment (80% incomplete response rate), whereas most patients without an elevation in calcitriol responded well to antiresorptive treatment (78% response rate: P < .001). There was no significant difference in the percentage of patients with metastatic bone disease among the 2 groups (49% vs. 55%, respectively). There was no difference in mortality between the 2 groups (P = .14). A weak but significant negative correlation was found between phosphorus and calcitriol (Pearson r = -0.261, P = .016). This correlation was only significant in patients without calcitriol elevation (Pearson r = -0.4, P = .0082). Also, a significant negative correlation was found between PTHrP and phosphorus, again only in patients without calcitriol elevation. DISCUSSION: In the setting of HCM, patients with calcitriol elevation are much less likely to respond to antiresorptive therapy than patients without calcitriol elevation. Because calcitriol elevation did not appear to be correlated with hypophosphatemia or elevated PTHrP, it would appear that calcitriol production under these conditions is autonomous, and not subject to normal physiological controls. These observations indicate that calcitriol elevations in patients with HCM have clinical significance.
引用
- Chukir T, Liu Y, Hoffman K, et al. Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors. J Clin Endocrinol Metab. 2020. PMID: 31841590. doi:10.1210/clinem/dgz278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。